CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$1.06
-0.04 (-3.64%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 13, 2026
11d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTOR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CTOR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1.60
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$0.99
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $1.06, which is considered slightly low relative to its 30-day fair value range of $1.05 to $1.14. The stock's valuation (Forward PE: 1.6) is in line with its historical norms (1.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CTOR is in a strong downtrend. Immediate support is located at $1.01, while resistance sits at $1.21. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+466.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTOR is in a strong downtrend. Immediate support is located at $1.01, while resistance sits at $1.21. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+466.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$1.05 -
$1.14
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding CTOR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 466.0% below Wall St target ($6.00)
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$1.05 -
$1.14
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.01
Resistance Level
$1.21
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
1.58
Wall Street Target
$6.00
(+466.0%)
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
1.6 vs 1.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$1.04
(-2%)
2-Year Target
$1.03
(-3%)
3-Year Target
$1.01
(-4%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
$1.09
(+3%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.6 to 1.7
Stabilization Target:
$1.14
(+7.5%)
PE Expansion Potential:
+7.5%
Last updated: February 01, 2026 2:01 PM ET
Data refreshes hourly during market hours. Next update: 3:01 PM
Data refreshes hourly during market hours. Next update: 3:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced CTOR Option Strategies
Professional options setups generated by AI based on today's CTOR price and gamma walls.